Weber G F, Waxman D J
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115.
Arch Biochem Biophys. 1993 Dec;307(2):369-78. doi: 10.1006/abbi.1993.1602.
The alkylating agent BCNU [1,3-bis(2-chloroethyl)-1-nitrosourea] can be inactivated through denitrosation reactions catalyzed by both cytosolic and microsomal enzymes. While previous studies have identified a class mu glutathione S-transferase [rat transferase 4-4 (Yb2)] as a major catalyst of the cytosolic denitrosation reaction, the enzymatic catalysts of BCNU denitrosation in microsomal membranes have not been identified. In the present study, both NADPH and glutathione (GSH) were found to support BCNU denitrosation catalyzed by isolated rat liver microsomes. Treatment of rats with the microsomal enzyme inducers phenobarbital and dexamethasone increased NADPH-dependent liver microsomal BCNU denitrosation up to fivefold without major effect on the GSH-dependent denitrosation activity. Although the NADPH-dependent activity was fully inhibited by antibody to NADPH-P450 reductase, purified NADPH-P450 reductase catalyzed BCNU denitrosation at rates that could only account for approximately 2-3% of the microsomal activity. Other experiments, including selective inhibition of NADPH-dependent microsomal BCNU denitrosation by chemical and antibody inhibitors of cytochrome P450, competitive inhibition of P450-catalyzed cyclophosphamide and ifosfamide activation by BCNU, and reconstitution of the denitrosation reaction by purified P450 enzyme 2B1 (major phenobarbital-inducible P450 form), established an important role for cytochrome P450 in BCNU denitrosation. By contrast, GSH-dependent microsomal BCNU denitrosation was unaffected by cytochrome P450 inhibitors, but was inhibited, with varying degrees of selectivity, by the microsomal glutathione S-transferase inhibitors ethacrynic acid, bromosulfophthalein, and indomethacin. These studies establish that BCNU inactivation can be catalyzed by two independent microsomal enzyme systems and suggest that therapeutically useful improvements in BCNU antitumor activity might be achieved through differential inhibition of these enzyme systems in tumor as compared to extratumoral sites.
烷化剂卡莫司汀[1,3-双(2-氯乙基)-1-亚硝基脲]可通过胞质和微粒体酶催化的脱亚硝基反应失活。虽然先前的研究已确定μ类谷胱甘肽S-转移酶[大鼠转移酶4-4(Yb2)]是胞质脱亚硝基反应的主要催化剂,但微粒体膜中卡莫司汀脱亚硝基反应的酶催化剂尚未明确。在本研究中,发现烟酰胺腺嘌呤二核苷酸磷酸(NADPH)和谷胱甘肽(GSH)均能支持分离的大鼠肝微粒体催化的卡莫司汀脱亚硝基反应。用微粒体酶诱导剂苯巴比妥和地塞米松处理大鼠,可使NADPH依赖的肝微粒体卡莫司汀脱亚硝基反应增加至五倍,而对GSH依赖的脱亚硝基活性无重大影响。虽然NADPH依赖的活性被抗NADPH-P450还原酶抗体完全抑制,但纯化的NADPH-P450还原酶催化卡莫司汀脱亚硝基反应的速率仅约占微粒体活性的2%-3%。其他实验,包括用细胞色素P450的化学抑制剂和抗体抑制剂选择性抑制NADPH依赖的微粒体卡莫司汀脱亚硝基反应、卡莫司汀对P450催化的环磷酰胺和异环磷酰胺活化的竞争性抑制,以及用纯化的P450酶2B1(主要的苯巴比妥诱导型P450形式)重建脱亚硝基反应,均证实细胞色素P450在卡莫司汀脱亚硝基反应中起重要作用。相比之下,GSH依赖的微粒体卡莫司汀脱亚硝基反应不受细胞色素P450抑制剂的影响,但受微粒体谷胱甘肽S-转移酶抑制剂依他尼酸、溴磺酞钠和吲哚美辛的抑制,抑制程度不同且具有选择性。这些研究证实卡莫司汀失活可由两个独立的微粒体酶系统催化,并表明与肿瘤外部位相比,通过在肿瘤中选择性抑制这些酶系统,可能在治疗上有效提高卡莫司汀的抗肿瘤活性。